ArticleACS omega2026
Stability-Indicating HPLC Method for Simultaneous Determination of Sulfadimethoxine and Ormetoprim in an Oral Solution.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A stability-indicating HPLC method was developed and validated for the simultaneous determination of sulfadimethoxine (SDM) and ormetoprim (OMP) in an oral solution. Chromatographic separation was achieved on a C18 column using 0.05% (v/v) phosphoric acid in water and methanol as the mobile phase under gradient elution, with diode array detection at 275 nm. Retention time modeling was applied to optimize the separation of the two analytes from the nine degradation products generated during forced degradation studies. Under the optimized chromatographic conditions, the retention times of the OMP and SDM were approximately 14.76 and 21.94 min, respectively. The method was validated in accordance with the ICH guidelines for specificity, linearity, accuracy, precision, and robustness. Average recoveries ranged from 98.62% to 99.87% for OMP and from 99.74% to 101.14% for SDM, and the % RSD values for both analytes were below 2%. All of the evaluated performance characteristics met the predefined acceptance criteria. Forced degradation studies under acidic, alkaline, oxidative, thermal, and photolytic conditions demonstrated that the analyte peaks were well-resolved from degradation products, supporting the stability-indicating capability of the method. GAPI and AGREEprep assessments indicated a moderate greenness profile, with an AGREEprep score of 0.40, while a BAGI score of 72.5 indicated good practical applicability. The method was further applied to a 6-month accelerated stability study of the oral solution. These results support the suitability of the proposed procedure for the simultaneous quantification of SDM and OMP in an oral solution and for stability evaluation under the conditions studied.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.